ArticleJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2026
Local recurrence and locoregional metastases as precursors of death by cutaneous squamous cell carcinoma.
Article in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn cutaneous squamous cell carcinoma (cSCC), there is a paucity of data regarding local recurrence (LR) and regional lymph node metastasis (LM) as precursors to tumor death. PATIENTS AND
methodsWe estimated parameters of a multistate model with a proportion of patients without risk of progression using maximum likelihood. For seven risk factors, the relative risks of progression to LR, LM, and LR&LM were compared with the relative risks of cSCC death among patients with progression.
resultsOf the 1,400 patients, 124 (8.9%) were diagnosed with either LR (68), LM (42), or LR&LM (14). cSCC-specific death occurred in 33 patients (2.4%), 10 by LR, 14 by LM, and 9 by LR&LM, among these 10 distant metastases. Conversely, 493 patients (35.2%) died from other causes. The risk of death from cSCC was 14.7% for LR, 33.3% for LM, and 64.3% for LR&LM. The median time to disease-related death was 1.3 years.
conclusionsThe risk of progression is limited to approximately 25% of patients. LM has been found to be associated with a higher risk of disease-specific death in comparison to LR. The median interval from progression to disease-specific death was found to be 1.3 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.